New Resuscitation Fluid Shows Potential in Early Testing
This synthetic nanoparticle fluid could eventually offer an alternative for patients facing emergency blood shortages.
Updated on Oct. 30, 2026 in Stroke
Live Poll
Would you trust a synthetic blood substitute derived from egg and soybean oil?
A researcher has developed an experimental fluid designed to revive subjects from clinical death. The technology, which could eventually address blood supply challenges, is now moving toward human clinical trials.
Why it matters
Blood shortages regularly strain hospitals, such as University Health KC, which consumes at least 500 units of blood per day. This new approach seeks to provide a temporary alternative to traditional blood transfusions.
In a preclinical study, a fluid made of soybean oil, egg lecithin, and egg yolk demonstrated a 100% survival rate in mice drained to the point of clinical death. The safety and effectiveness of this approach in humans are still being investigated.
The players
Dr. Cuthbert Simpkins
The founder of Vivacelle Bio who developed the VBI-1 fluid and the earlier VBI-S invention.
University Health KC
A healthcare provider in Kansas City that utilizes at least 500 units of blood daily.
The details
The experimental fluid, known as VBI-1, utilizes nanoparticle technology to deliver oxygen and sustain life without the reperfusion injury often linked to brain damage during blood reinfusion. Unlike traditional transfusions, this synthetic mixture is intended to stabilize vital functions after extreme blood loss. Researchers are testing this method to determine if it can safely bridge the gap when donor blood is unavailable.
Timeline
2020: Blood shortages began repeatedly hitting low levels in communities.
2027-2028: Expected timeframe for human clinical trials.
2031: Targeted FDA approval and market release.
Health Landscape
This development represents a novel attempt to solve long-standing blood supply shortages that frequently impact hospital operations. It sits within a pipeline of oxygen-carrying therapeutics that aim to supplement or replace donor blood in emergency scenarios.
This technology remains in early development and is not currently available for patient use or clinical decision-making. Patients with concerns about emergency blood management should discuss standard hospital protocols and contingency plans with their physician.
The takeaway
While the experimental fluid shows promise in animal models for preventing organ damage, it is not yet a viable treatment for clinical use. It is a technology worth monitoring for updates as the research enters human testing phases.
What happens next
Human clinical trials for VBI-1 are expected to commence between 2027 and 2028.
Further reading
Learn more about the latest innovations in Stroke management.
Source note: This article includes information reported by WENG 98.1FM, 107.5 FM & 1530 AM.
Live Poll
Would you trust a synthetic blood substitute derived from egg and soybean oil?
